Structure Therapeutics CEO talks obesity pill and more
Ray Stevens, CEO of Structure Therapeutics Inc., during a Bloomberg Television interview at the JPMorgan Healthcare Conference in San Francisco,…
Biotechnology and pharmaceuticals
Another Alliance Between Healthcare and AI Indicates Why Pharma Stocks Could Make a Comeback
Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating the early detection of lung cancer marks the latest way…
Novo Nordisk and Pfizer executives weigh in
US President Donald Trump arrives to make an announcement in the Roosevelt Room of the White House in Washington, DC,…
Keeping US biotech ahead of China could help patients with rare diseases: experts
The growth of China's biotech sector has been astonishing. Beijing is pumping money into the industry, supporting research efforts and…
Novo Nordisk shares rise after launch of anti-obesity pill Wegovy
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, on January 15, 2026. George Frey…
Novo Nordisk CEO talks GLP-1 pill at JPMorgan conference
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
Men's makeup becomes popular on TikTok, Ulta and Sephora capitalize on it
Pixdeluxe | E+ | fake images It often starts small. A little concealer. A tinted moisturizer. Maybe an eyebrow gel…
What to expect from the pharmaceutical industry at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar “Mike” Doustdar, Eli Lilly CEO David Ricks and Commerce Secretary Howard Lutnick listen as…
Abivax Stock Rises to Become Top Biotech Acquisition Target
Europe's best-performing blue-chip stocks in 2025 are expected to be bought by a larger peer, in a deal analysts say…
Novo Nordisk's first GLP-1 obesity pill launched in the US
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, outside Copenhagen, on November…